MedPath

Optimal regimens of sulfamethoxazole-trimethoprim for prophylaxis of pneumocystis pneumonia in patients with systemic rheumatic diseases: multi-center randomized open label trial

Not Applicable
Conditions
Pneumocystis pneumonia
Registration Number
JPRN-UMIN000031513
Lead Sponsor
Juntendo University School of Medicin
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
89
Inclusion Criteria

Not provided

Exclusion Criteria

1.Have contraindications to SMX/TMP 2.Have a history of PCP 3.Have received biologic agents 4.Have uncontrollable complications 5.Body weight below 40 kg 6.Being pregnant or a nursing woman 7.Being unable to start SMX/TMP within 14 days of starting prednisolone 8.Unable to give informed consent

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The primary endpoint was non-incidence rate of PCP at week 52.
Secondary Outcome Measures
NameTimeMethod
The secondary endpoint was drug continuation rate at week 52.
© Copyright 2025. All Rights Reserved by MedPath